TMS Co., Ltd.

Equities

4891

JP3544960002

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 22:30:00 2024-07-17 EDT			5-day change	1st Jan Change
255 ^JPY	+1.19%		+0.39%	+35.64%

07-03	TMS to Make Upfront Payment to Hokkaido University for Licensing Agreement; Shares Fall Over 3%	MT
07-03	TMS Enters into Exclusive License Agreement with Hokkaido University to In-License Novel Therapeutic Candidate for Spinal Cord Injury	CI

TMS Co., Ltd. announced that it expects to receive ¥684.324069 million in funding

January 10, 2024

TMS Co., Ltd. announced a private placement to issue 3,659,487 shares at a issue price 187 yen per share for a gross proceeds JPY 684,324,069 on January 11, 2024. The transaction included participation from RTW Master Fund, Ltd for 2,083,830 shares, RTW Innovation Master Fund, Ltd for 1,524,886 shares and RTW Biotech Opportunities Ltd for 50,771 shares. The transaction is expected to close on January 31, 2024.

Latest news about TMS Co., Ltd.

TMS to Make Upfront Payment to Hokkaido University for Licensing Agreement; Shares Fall Over 3%	07-03	MT
TMS Enters into Exclusive License Agreement with Hokkaido University to In-License Novel Therapeutic Candidate for Spinal Cord Injury	07-03	CI
TMS Co., Ltd. Announces Dosing to the First Subject in TMS-008 Phase I Clinical Trial	06-19	CI
Equinor: contract with Vallourec in Brazil	06-17	CF
Equinor: contract with Vallourec in Brazil	06-17	CF
Tennant Minerals Produces 'High-Grade' Concentrates from Bluebird Discovery Samples	05-20	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	05-14	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	05-03	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	05-01	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	04-29	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	04-26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	04-25	MT
Jefferies Adjusts TMS’ Price Target to 760 Yen From 730 Yen, Keeps at Buy	04-15	MT
Tennant Minerals Raises AU$4.8 Million for Drilling, Target Testing; Shares Down 4%	04-08	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04-04	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	03-27	MT
Tennant Minerals Finds 23% Copper Concentrate, 1.5G/T Gold at Bluebird Project	03-26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	03-26	MT
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise	03-25	MT
Tennant Minerals to Commence Next Phase of Drilling at Barkly Project; Shares Down 3%	03-10	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat	03-01	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	02-29	MT
TMS Co., Ltd. Submits Clinical Trial Plan Notification for TMS-008 Phase I Clinical Trial in Japan	02-29	CI
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading	02-27	MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading	02-26	MT

Chart TMS Co., Ltd.

Duration

Period

More charts

Company Profile

TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.

Sector

Biotechnology & Medical Research

Calendar

2024-10-10 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

252 JPY

Average target price

760 JPY

Spread / Average Target

+201.59%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TMS CO., LTD.	+35.64%	62.52M
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research